EQS-News Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
EQS Group-News: Relief Therapeutics Holdings AG / Key word(s): Personnel
Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
Geneva, Switzerland, September 04, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Gilles Della Corte, M.D., as Chief Medical Officer, effective immediately.
Raghuram (Ram) Selvaraju, Chairman of the Board of Relief, said: "We welcome Gilles to Relief. He brings extensive knowledge in clinical trials planning, conduct from early stage to market and understands all stages of the product development process as well as the importance of planning early to lay the foundation for a successful product launch. He has served in a variety of roles at pharmaceutical companies as well as CROs and has advised many companies, including Relief, on clinical trials strategy and planning. He also has strong expertise in regulatory preparations, including engagement with regulatory authorities and relationship management with CROs and other clinical trial vendors. He will be a great asset to Relief as aviptadil advances in clinical development in Europe and the U.S. and as we hopefully prepare submissions for marketing approval soon."
Dr. Della Corte brings over 40 years of professional experience, 30 of that in the biopharmaceutical industry. Dr. Della Corte held several senior clinical research positions at Merck Serono (previously Serono), where he was responsible for the development from proof of concept to life cycle management of projects in several disease areas, including cardiology, rheumatology, oncology and endocrinology. Earlier in his career, he also held positions of increasing responsibility at several CROs, pharmaceutical and start-ups companies including Rhone-Poulenc-Rorer, Servier, Solvay Pharma as well as Phoenix Life Sciences, Larime, Omnicare Clinical Research, Therapharm, Anergis. In 2016, Dr. Della Corte founded Dellmed Consulting, providing strategic advices and hands-on support for clinical development in various therapeutic areas such as dermatology, oncology, allergy and for clinical research organization (CRO) selection, for companies ranging from biotech start-ups to well established pharmaceutical companies. Dr. Della Corte holds an M.D. from Paris-Sud University (Paris XI) and is a Board-certified cardiologist with ten years of hospital practice. At Relief, Dr. Della Corte will be responsible for the clinical development of aviptadil in Europe and coordinating closely with NeuroRx, which will continue to manage clinical trials in the U.S., as well as interactions with and submissions to regulatory authorities.